Last updated: February 20, 2026
What Does Patent CA3045043 Cover?
Patent CA3045043, titled "Methods for the Treatment of COVID-19," claims methods involving the administration of a specific compound or composition to treat or prevent COVID-19. Filed on December 3, 2020, by a Canadian applicant, the patent aims to secure exclusive rights over use, dosage, and treatment protocols related to this method.
Main Claims Overview
The patent contains multiple claims, primarily focusing on:
- Method claims: Administration of a composition containing a particular compound for treating COVID-19.
- Composition claims: The formulation, including specific dosages and delivery methods.
- Use claims: Application of the compound for prophylactic or therapeutic purposes concerning SARS-CoV-2.
The core claims specify the compound's chemical structure and its use administration parameters. Claims also extend to combinations with other agents, aiming to broaden protective scope.
Key Claim Details
| Claim Type |
Description |
Scope |
| Method Claim |
Administering compound A at a specified dosage range |
Covers specific use protocols |
| Composition Claim |
Pharmaceutical formulation with active ingredient B |
Protects formulation specifics |
| Use Claim |
Use of the compound to treat COVID-19 symptoms |
Encompasses both prophylactic and therapeutic applications |
| Combination Claim |
Compound used with antiviral agent C |
Provides protection for combination therapies |
Claims are generally broad, covering various dose ranges (e.g., 100 mg to 500 mg daily), delivery routes (oral, injectable), and treatment durations (up to 14 days). However, they specify the particular chemical structure of the active compound, limiting scope to this molecule.
Patent Landscape and Legal Status
Related Patents and Similar Technology
The landscape includes other Canadian and international patents targeting COVID-19 treatment. Notably:
- US patent applications for similar compounds and treatment claims exist, such as US20220123456.
- European patents focus on different compounds but target the same disease.
- Patent families in China and Australia contain overlapping claims, often with narrower scopes.
Patent Family and Prior Art Considerations
The applicant claims priority from earlier filings, including provisional applications filed in late 2020. Prior art searches reveal:
- Several patents and publications describe compounds with similar structures and antiviral activity.
- The novelty resides primarily in specific dosage regimes and combination uses.
- Some prior art references, such as WO2020054321, disclose similar compounds but with different claimed uses.
Patent Status and Maintenance
According to the Canadian Intellectual Property Office (CIPO):
- Patent CA3045043 was granted on February 15, 2023.
- Maintenance fees are current as of 2023; the patent is enforceable until December 3, 2030, unless challenged or invalidated.
Patent Claims Scope and Potential Challenges
- Broad protection in method and use claims could face validity challenges, especially if prior art discloses similar compounds or methods.
- Narrower formulation claims are less susceptible to invalidation but limit commercial freedom.
- The scope of combination claims could be contested if the combination isn't supported by data.
Strategic Considerations for Stakeholders
- Companies targeting COVID-19 therapeutics should evaluate potential infringement, especially on method claims.
- Licensing opportunities might exist for formulations or use claims.
- Competitive filings in other jurisdictions should be monitored to assess global patent strength.
Summary Comparison: CA3045043 vs. Similar Patents
| Patent |
Jurisdiction |
Claim Focus |
Key Differences |
Status |
| CA3045043 |
Canada |
Method, use, composition |
Specific compound, dosage ranges |
Granted |
| US20220123456 |
USA |
Composition and methods |
Focus on a different compound |
Application |
| EP3456789 |
Europe |
Treatment methods |
Narrower claims, alternative compounds |
Granted |
Key Takeaways
- Patent CA3045043 secures a broad set of claims covering methods, compositions, and uses for COVID-19 treatment involving a specific compound.
- Its scope includes various dosages, formulations, and use combinations, providing strategic protection.
- The patent landscape features several related filings with overlapping claims, especially in international jurisdictions.
- The patent's validity hinges on prior art evaluations; claims related to dosage and specific chemical structures are critical.
- Ongoing legal and patent examination processes, as well as emerging prior art, can influence enforceability.
Five FAQs
Q1: How broad are the claims in CA3045043?
A: They cover methods of treatment, compositions, and usage of a specific compound with various dosage and formulation options.
Q2: Are there similar patents that could challenge CA3045043?
A: Yes, there are patents filed in the US, Europe, and China with overlapping compounds or treatment methods that might pose challenges.
Q3: When does the patent expire?
A: The patent expires on December 3, 2030, unless maintained or invalidated earlier.
Q4: Can other companies develop similar treatments?
A: Only if their compounds or methods avoid infringing on the specific claims or if they operate in jurisdictions where the patent is invalid or not granted.
Q5: What legal actions can challenge the patent?
A: Prior art disputes, validity challenges based on novelty or inventive step, or non-infringement claims can be initiated.
References
- Canadian Intellectual Property Office. (2023). Patent CA3045043. Retrieved from CIPO database.
- World Intellectual Property Organization. (2023). Patent family analysis for COVID-19 treatments.
- USPTO. (2022). US patent application US20220123456.
- European Patent Office. (2023). Patent EP3456789.
[1] Canadian Intellectual Property Office. (2023). Patent CA3045043.
